CA-TALKDESK
Talkdesk®, Inc. , the cloud contact center for innovative enterprises, today announced $143 million in Series C funding from a combination of new and existing investors. The amount raised, and the company’s valuation of more than $3 billion, reflects both investor confidence in Talkdesk’s business and the strategic role that superior customer experience plays among top global brands.
New investors participating in this latest round include Franklin Templeton, Willoughby Capital, Skip Capital, Lead Edge Capital and Top Tier Capital Partners, along with existing partners Viking Global Investors and Threshold Ventures. In total, Talkdesk has raised $268 million over its funding rounds, strengthening its leadership position in the Contact Center as a Service (CCaaS) marketplace and solidifying the role of customer experience as a strategic differentiator for enterprises.
This latest investment follows a year of continued global growth, product development and market leadership for Talkdesk. Over the past 12 months Talkdesk has introduced more than 600 product innovations to the market including Talkdesk 20-in-20 , an ambitious release program to lead the contact center industry by starting 2020 with 20 product introductions in the first 20 weeks. Talkdesk’s culture of innovation led to 200 patent submissions in 100 days and continues to push customer service ahead with industry advancements like CXTalent and multiple awards .
The new funding will allow Talkdesk to capitalize on its current momentum and continue its global growth. The company plans to increase research and development spending and to invest in go-to-market, sales, marketing and channel development as Talkdesk continues to expand up-market.
Helping Brands Differentiate Through Customer Service During COVID-19
While companies have historically made significant investments in their contact centers as a means of differentiation through customer support, COVID-19 has served as a catalyst for accelerated investment in cloud-based solutions. Many consumer-facing brands have effectively lost their primary retail channel, making the need to provide world-class support a strategic imperative. As many enterprises move operations to a completely remote setting for the first time, Talkdesk’s cloud-native solutions ensure that agents can deliver an exceptional customer experience regardless of their location.
“The importance of providing an unparalleled customer experience has never been greater and this latest funding is a reflection of the criticality of this aspect as brands look for avenues for growth in our current environment,” said Tiago Paiva, chief executive officer, Talkdesk. “We are incredibly appreciative of the support and confidence of our investors, customers and partners who continue to endorse our vision of providing the industry’s most innovative and flexible solutions for the modern contact center. Lastly, I want to share my immense gratitude for the dedication and expertise of our employees who enable us to deliver for our customers, even during the most challenging times.”
"The global pandemic has fueled the importance of customer experience for business continuity. Talkdesk provides an innovative CX platform and solutions to help every organization provide the best possible and amazing customer experience,” said Mark Smith, chief executive officer and chief research officer, Ventana Research. “Our recognition of Talkdesk to receive the Ventana Research Digital Innovation Award in CX for 2020 is yet another example of the investment in innovation. The growth and funding is testament to the confidence and trust in the brand by customers and partners who have committed to Talkdesk."
The Talkdesk team consists of some of the world’s top authorities in the area of CCaaS and customer experience. The organization is a strategic and reliable provider to its customer base of more than 1,800 innovative customers in 75 countries including IBM, Acxiom, 2U, Trivago and Peloton.
Supporting Investor Quotes:
“We are excited to join Talkdesk in its journey to reimagine a critical element of business to consumer communications infrastructure, as businesses seek to enhance their relationships with customers with next generation digital engagement tools. Talkdesk’s market potential is large, and its business model is promising,” said Jonathan Curtis, vice president, research analyst and portfolio manager with Franklin Templeton’s Franklin Equity Group.
“We have been incredibly impressed by Talkdesk and the remarkable growth and scale the company has achieved over the last few years,” said Morgan Rutman, president, Willoughby Capital. “The company’s solutions are mission-critical across a range of industries during these challenging times. We are excited to support Tiago and the team through the next stage of the company’s evolution.”
"With a best-in-class product, Talkdesk’s rapid growth in the enterprise contact center segment is extremely impressive,” said Kim Jackson, founder, Skip Capital. “We are excited about accelerating cloud adoption, and as businesses of all sizes look for tools to help with a shift to remote work, Talkdesk’s product suite is highly compelling. We are thrilled to join the Talkdesk team on their journey."
"Talkdesk is a step above the outdated, legacy contact center systems and has quickly established itself as the vendor-of-choice. We're excited to partner with the company as its suite of products reaches an even greater scale," said Mitchell Green, managing partner, Lead Edge Capital. “Talkdesk is experiencing explosive adoption of its technology, and it is no surprise given the pain points its solving for companies, large and small.”
“Talkdesk is leveraging software and innovation to disrupt the traditional call center,” said Garth Timoll, managing director, Top Tier Capital Partners. “The company has emerged as a clear leader in the CCaaS sector and Top Tier Capital Partners is excited to support Talkdesk’s continued growth.”
"Threshold Ventures partners with exceptional entrepreneurs who have a vision for transformative, market-changing solutions. Tiago and the Talkdesk team are innovatively pushing CCaaS applications to a new level,” said Josh Stein, partner, Threshold Ventures. “Since leading their Series A financing, we’ve had a front row seat to watch Talkdesk emerge as an undisputed leader in the large CCaaS market."
Additional Resources:
- Hear direct from customers why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
- Read more on how to boost support for your customers and employees when the unexpected happens
- Talkdesk 20-in-20 is revolutionizing contact center industry with 20 products in the first 20 weeks of 2020
-
Check out Talkdesk’s prestigious list of awards and recognition
, including recent recognition as a Leader in the 2019 Gartner CCaaS Magic Quadrant, North America
Tweet this : .@Talkdesk raises $143M in Series C funding. Valuation of $3B+ highlights the strategic role of superior customer experience among top global brands. https://bit.ly/3eUo5me
Social Networks:
- Web: https://www.talkdesk.com
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is the cloud contact center for the customer-obsessed. Combining enterprise performance with consumer simplicity, Talkdesk easily adapts to the evolving needs of support and sales teams and their end-customers, resulting in higher customer satisfaction, productivity and cost savings. Over 1,800 innovative companies around the world, including IBM, Acxiom, 2U, Trivago and Peloton, rely on Talkdesk to make customer experience their competitive advantage. Learn more and request a demo at www.talkdesk.com .
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
